Fig 5. ACY-957 enhances the anti-leukemic activity of azacitidine in MOLM-13 xenograft model.
(A-B) Female Crl:NU(NCr)-Foxn1nu mice implanted with MOLM-13 cells (n = 10/group) were treated with vehicle, ACY-957 (125 mg/kg, po, daily), azacitidine (5.5 mg/kg, iv, bi-weekly), or the combination of ACY-957 plus azacitidine for 28 days. (A) Tumor volume was monitored and TTE for each mouse was calculated and plotted as described in the Materials and Methods. Combination treatment of ACY-957 with azacitidine significantly increased the survival of MOLM-13 model over azacitidine alone (P < 0.0001) as well as ACY-957 alone (P = 0.005). (B) Body weight was measured on the indicated days and percentage of body weight plotted. Mean ± SD, n = 10. Statistical analysis was performed by Log-rank (Mantel-Cox) test.